# A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

> **NCT03981536** · PHASE1 · UNKNOWN · sponsor: **AL-S Pharma** · enrollment: 18 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** AP-101

## Key facts

- **NCT ID:** NCT03981536
- **Lead sponsor:** AL-S Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-10
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-02
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981536, "A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03981536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*